Compare Dominion Energy Inc (D) vs TG Therapeutics Inc (TGTX) Price & Performance

Dominion Energy (D) trades at $61.53, down 0.76% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with revenue growth from $14.5B in 2024 to $16.5B in 2025 and net income margin improving to 18.16%. Analyst consensus is mixed with 36% buy ratings but a $71.56 price target suggesting 16% upside. The pending merger with NextEra Energy dominates recent news coverage, creating both opportunity and regulatory uncertainty.

The stock presents a value opportunity with reasonable valuation multiples (P/E 21.37, P/S 2.96) and consistent profitability, though technical indicators suggest near-term pressure. Key risks include merger approval uncertainty, high debt levels, and interest rate sensitivity. The dividend yield of approximately 4.4% provides income support while investors await merger resolution and continued execution on data center and renewable energy investments.

TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.

The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.